Cargando…
Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation
The “breakthrough therapy” designation (BTD) is a recent mechanism implemented by the United States Food and Drug Administration (FDA) to expedite access to drugs that address unmet needs. The purpose of this study is to describe pharmacists’ knowledge of FDA drug-approval standards and knowledge an...
Autores principales: | Herink, Megan C., Johnston, Kirbee, Breninger, Kristin, Wu, Erin, Irwin, Adriane N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610476/ https://www.ncbi.nlm.nih.gov/pubmed/36287447 http://dx.doi.org/10.3390/pharmacy10050126 |
Ejemplares similares
-
Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update
por: Paquin, Ryan S, et al.
Publicado: (2022) -
FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology
por: Sheikh, Ayesha, et al.
Publicado: (2022) -
Celebrating a breakthrough: the first-ever FDA-approved treatment for geographic atrophy: a correspondence
por: Khan, Abdul Moiz, et al.
Publicado: (2023) -
FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021) -
Celebrating breakthrough in dental diagnostics: FDA approval of an AI model for diagnosis of periodontal diseases: A correspondence
por: Khan, Ayesha, et al.
Publicado: (2023)